


## What are Antibody-Drug Conjugates ?

Antibody-Drug Conjugates (ADCs) are the outcome of merging monoclonal antibodies with cytotoxic drugs using a linker. The monoclonal antibody selectively targets antigens overexpressed on cancer cells, ensuring precise payload delivery while sparing healthy tissues.




~9.7

US\$ Billion market

# A fast-emerging class of therapeutic agents...

ADCs in clinical

development



*Clinical stage of current ADC under development* 

524

... however, they represent about 16% of all the therapeutic antibodies currently under clinical development.

ADCs currently on the market



## ADCs currently on the European market

### **Ovarian Cancer:**

1 marketed ADC 58 under development

> **Breast Cancer:** 2 marketed ADC 99 under development

**Leukaemia:** 2 marketed ADC 21 under development **Urothelial cancer:** 1 marketed ADC 23 under development

#### Lymphoma: 1 marketed ADC 37 under development

**Cervical Cancer:** 1 marketed ADC 17 under development



**Triple-Negative Breast Cancer:** 1 marketed ADC 39 under development **Diffuse Large B-Cell Lymphoma:** 1 marketed ADC 14 under development



Source: Globaldata / Data from May 2023